San Francisco-based Meissa Vaccines has announced it is intiating pre-clinical studies of its live attenuated vaccine (LAV) against SARS-CoV-2, the virus which causes Covid-19.
The vaccine candidate, MV-014-210, is a intranasal, adjuvant free vaccine, which was build on Meissa’s respiratory syncytial virus (RSV) vaccine platform.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Meissa also announced it has completed its pre-investigational new drug application with the US Food and Drug Administration.
The company’s CEO and co-founder Martin Moore noted: “The Covid-19 vaccine pipeline is dominated by non-replicating vaccines, while live attenuated vaccines are known to induce long-lasting immunity after a single adjuvant-free dose, presenting an economical and effective solution to this global pandemic.
“A single dose of MV-014-210 may be sufficient to generate immunity against SARS-CoV-2. Furthermore, building our Covid-19 vaccine candidate on our RSV vaccine platform provides safety advantages compared to a live attenuated coronavirus approach.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
